The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children. This approach is only made possible by contrasting the DNA of children with severe developmental disorders of unknown genetic cause, with the DNA from individuals without overt developmental disorders. These research participants were drawn from around the globe.
There are over 1,000 different genetic causes of developmental disorders that have already been identified, but these only account for about one third of all children with such disorders.
Most individual developmental disorders are so rare that they confound efforts to uncover their causes, hence the importance of taking a nationwide approach.
In the study, published in Nature Genetics, the DDD team analysed samples from more than 4,000 families from across the UK and Republic of Ireland with at least one child affected by a developmental disorder and applied a computational strategy to identify clusters of affected children that had similar clinical characteristics and shared damaging genetic variants in the same gene. Comparing the variants observed in these genes in the affected children with genetic variation observed in over 60,000 research participants - who have agreed to share their genetic data to support medical research - allowed the team to identify four previously uncharacterised genetic disorders.
The power of the study is built on the contribution of many thousands of people who have agreed to share genetic data to support medical research, and the work of the Exome Aggregation consortium (ExAC) in bringing those data together and making them available widely.
"With the contribution of many thousands of people to medical research, we have the power to uncover mutations behind some devastating conditions," says Dr Matthew Hurles, project leader at the Wellcome Trust Sanger Institute. "Their altruism can unlock the secrets in our genomes, providing answers to families desperate to understand their child's condition and enabling those families to access support and engage in further studies researching possible therapeutic strategies."
The DDD team focused on genetic disorders where a child inherits a damaged copy of a gene from both parents, neither of whom have the disorder because they also carry an undamaged 'back-up' copy of the gene. Defining genetic variants that cause such rare disorders has previously most often relied on studies of extensive family trees, where several people are affected with the same disorder, or of studies of unrelated individuals sharing the same, very distinctive, disorder. For many developmental disorders, these requirements are not met.
The team screened genes encoding over 18,000 proteins in the families' genomes, searching for variants that might prevent each protein from working, and uncovered 74 genes in which mutations might play a role. For four of these genes, comparisons with the ExAC dataset revealed that these damaging variants were greatly enriched in the affected children compared to individuals without developmental disorders.
The children's conditions were systematically clinically assessed to objectively characterise the disorder. This systematic assessment was essential for the large-scale computational analysis to discover rare disorders, especially to find those with less consistent or non-specific clinical presentations. Although genetic diagnosis doesn't initially bring new treatments, it helps families understand their child's disorder, can help them to access other support and allows them to engage in further studies researching possible therapeutics.
The damaging variants in children with developmental disorders affected genes involved in brain development, configuring of the heart and other organs in early embryonic development, and bone growth. For each of the four new disorders, additional support came from observing that mice having a mutation in the equivalent gene shared many characteristics that resembled the human condition.
"New strategies for discovering the genetic causes of rare disease are desperately needed," says Dr Daniel MacArthur, Assistant Professor at Harvard Medical School and the coordinator of the ExAC project, who was not involved in the study. "This study shows the value of clever analysis methods, together with genetic data from populations around the world from the ExAC project, to find answers for rare disease families."
Notes to Editors
Awaki N, McRae et al. (2015) Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4,125 families. Nature http://dx.
Wellcome Trust Sanger Institute, Cambridge, UK
MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland
Sheffield Regional Genetics Services, Sheffield Children's NHS Trust, Sheffield, UK
Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK
North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London, UK
West Midlands Regional Genetics Service, Birmingham Women's NHS Foundation Trust, Birmingham, UK
South East Thames Regional Genetics Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
Wessex Clinical Genetics Service, University Hospital Southampton, Princess Anne Hospital, and Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury District Hospital, and Faculty of Medicine, University of Southampton, Southampton, UK
Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA, USA
Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne, UK
West of Scotland Regional Genetics Service, NHS Greater Glasgow and Clyde, Institute Of Medical Genetics, Yorkhill Hospital, Glasgow, UK
North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street Hospital, London, UK
Peninsula Clinical Genetics Service, Royal Devon and Exeter NHS Foundation Trust, Clinical Genetics Department, Royal Devon & Exeter Hospital (Heavitree), Exeter, UK
Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
Deciphering Developmental Disorders Project
DDD membership described in Supplementary Note
Funding: The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (grant number WT098051). Please see the paper for further funding details.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. http://www.
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. http://www.